AstraZeneca Q2 profit declined to $350 millionStaff Writer | July 26, 2018
AstraZeneca reported that its profit for the second quarter attributable to owners of the parent declined to $350 million from $477 million in the same quarter last year.
AstraZeneca Earnings per $0.25 ordinary share decreased to $0.27
Core earnings per share for the quarter were $0.69, down 21 percent from last year.
Profit before tax declined 16 percent to $412 million from $492 million in the prior year.
However, total revenue for the quarter rose 2 percent to $5.16 billion from $5.05 billion in the same period last year.
The company's board has recommended an unchanged first interim dividend of $0.90 per ordinary share.
Looking ahead to fiscal 2018, AstraZeneca reiterated its outlook for core earnings per share of $3.30 to $3.50, and full-year product sales to increase in low single-digit percentage, at constant currency rates. ■